Lantern Pharma Inc. (LTRN)
| Market Cap | 25.70M -41.7% |
| Revenue (ttm) | n/a |
| Net Income | -18.65M |
| EPS | -1.63 |
| Shares Out | 12.78M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 90,801 |
| Open | 2.050 |
| Previous Close | 2.020 |
| Day's Range | 1.960 - 2.100 |
| 52-Week Range | 1.110 - 4.703 |
| Beta | 2.33 |
| Analysts | Strong Buy |
| Price Target | 17.50 (+770.65%) |
| Earnings Date | Aug 14, 2026 |
About LTRN
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for LTRN stock is "Strong Buy." The 12-month stock price target is $17.5, which is an increase of 770.65% from the latest price.
News
Lantern Pharma reports Q2 EPS (57c) vs (40c) last year
Cash, cash equivalents, and marketable securities of approximately $7.4 million as of June 30, 2026. Funding received in the second quarter consisted of approximately $4.4 million in gross proceeds fr...
Lantern Pharma Earnings Call Transcript: Q2 2026
Clinical programs advanced with strong AI integration, including a new AI spin-out and multiple regulatory clearances. Operating expenses fell 25% year-over-year, but net loss rose due to non-cash warrant expenses. Open-Medicine AI is set for independent growth and capital raising.
Lantern Pharma Quarterly report: Q2 2026
Lantern Pharma has published its Q2 2026 quarterly earnings report on August 14, 2026.
Lantern Pharma Earnings release: Q2 2026
Lantern Pharma released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
Lantern Pharma Slides: Q2 2026
Lantern Pharma has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 14, 2026.
Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update
DALLAS--(BUSINESS WIRE)--Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update.
Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET
DALLAS--(BUSINESS WIRE)--Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET.
Lantern Pharma establishes Open-Medicine AI as separate company
Lantern Pharma (LTRN) announced the formal creation of Open-Medicine AI and the execution of commercial licensing agreements between OMAI and Lantern Pharma. The agreements, which have received Lanter...
Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine
DALLAS--(BUSINESS WIRE)--Open Medicine AI is launched as separate entity by Lantern Pharma.
Lantern Pharma to advance EMA-cleared Phase 1b/2 trial of LP-184
Lantern Pharma (LTRN) announced that an investigator-initiated Phase 1b/2 clinical trial of its lead drug candidate LP-184 in advanced, recurrent bladder cancer has been cleared by the European Medici...
Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer
DALLAS--(BUSINESS WIRE)--EMA Phase 1b/2 Clinical Trial for LP-184.
Lantern Pharma receives USPTO notice of allowance for patent of LP-184
Lantern Pharma (LTRN) announced that the United States Patent and Trademark Office, USPTO, has issued a Notice of Allowance for U.S. Patent Application No. 17/230,821, titled “Methods for the Treatmen...
Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence and genomic data to develop targeted cancer therapies, today annou...
Lantern Pharma launches ZetaOmics computational-biology module
Lantern Pharma (LTRN) announced the launch of ZetaOmics, the computational-biology module of its multi-agentic AI co-scientist platform, withZeta.ai. ZetaOmics introduces an autonomous “Computational ...
Lantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent “Computational Biologist” That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced the launch of ZetaOmics, the computational-biology module of its mu...
Lantern Pharma Slides: Corporate presentation
Lantern Pharma has posted slides in relation to its latest quarterly earnings report, which was published on July 1, 2026.
Lantern Pharma files to sell 2.24M shares of common stock for holders
16:31 EDT Lantern Pharma (LTRN) files to sell 2.24M shares of common stock for holders
Lantern Pharma Registration statement: Registration filing
Lantern Pharma filed a registration statement on June 12, 2026, providing details about a securities offering with the SEC.
Lantern Pharma reports data, updates from Phase 2 Harmonic trial on LP-300
Lantern Pharma (LTRN) reported clinical data and updates in the form of a presentation from its ongoing Phase 2 Harmonic trial evaluating LP-300 in combination with carboplatin and pemetrexed in…
Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer
DALLAS--(BUSINESS WIRE)--Harmonic Presentation in form of 8K.
Lantern receives successful response to Type C meeting from FDA on LP-300
Lantern Pharma (LTRN) announced that it has received a successful response to its recent Type C meeting request from the U.S. Food and Drug Administration, FDA, focused on the ongoing…
Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced that it has received a successful response to its recent Type C mee...
Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates
DALLAS--(BUSINESS WIRE)--Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates.
Lantern Pharma Earnings release: Q1 2026
Lantern Pharma released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
Lantern Pharma Quarterly report: Q1 2026
Lantern Pharma has published its Q1 2026 quarterly earnings report on May 15, 2026.